Literature DB >> 15805382

A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.

Janet A Englund1, Emmanuel B Walter, Mary P Fairchok, Arnold S Monto, Kathleen M Neuzil.   

Abstract

BACKGROUND: Trivalent inactivated influenza vaccine (TIV) is recommended for all children ages 6 to 23 months. Delivering 2 doses of TIV at least 4 weeks apart to young children receiving this vaccine for the first time is challenging.
METHODS: We compared the immunogenicity and reactogenicity of the standard 2-dose regimen of TIV administered in the fall with an early schedule of a single spring dose followed by a fall dose of the same vaccine in healthy toddlers 6 to 23 months of age. Children were recruited in the spring to be randomized into either the standard or early schedule. An additional group was also enrolled in the fall as part of a nonrandomized standard comparison group. The 2002-2003 licensed TIV was administered in the spring; the fall 2003-2004 vaccine contained the same 3 antigenic components. Reactogenicity was assessed by parental diaries and telephone surveillance. Blood was obtained after the second dose of TIV for all children. The primary outcome measure was antibody response to influenza A/H1N1, A/H3N2, and B after 2 doses of vaccine, as determined by hemagglutination-inhibition titers > or =1:32 and geometric mean titer (GMT).
RESULTS: Two hundred nineteen children were randomized to receive either the standard or early TIV schedule; 40 additional children were enrolled in the fall in the nonrandomized standard group. Response rates in the combined standard versus early groups were similar overall: 78% (GMT: 48) vs 76% (GMT: 57) to H1N1, 89% (GMT: 115) vs 88% (GMT: 129) to H3N2, and 52% (GMT: 24) vs 60% (GMT: 28) to B. Reactogenicity after TIV in both groups of children was minimal and did not differ by dose, age, or time between doses. Reaction rates were higher in those receiving TIV and concomitant vaccines compared with those receiving TIV alone. Overall rates of fever >38 degrees C axillary and injection-site pain, redness, or swelling were 5.4%, 3.1%, 0.9%, and 1.1%, respectively.
CONCLUSIONS: When the spring and fall influenza vaccines had the same 3 antigenic components, the early vaccine schedule resulted in similar immunogenicity and reactogenicity compared with the standard schedule. When the vaccine components do not change between years, initiating influenza vaccine in the spring at the time of routine office visits would facilitate full immunization of children against influenza earlier in the season.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805382     DOI: 10.1542/peds.2004-2373

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

1.  Influenza vaccine recommendations for children and youth for the 2008-2009 season.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-09       Impact factor: 2.471

2.  Influenza vaccine recommendations for children and youth for the 2008-2009 season.

Authors: 
Journal:  Paediatr Child Health       Date:  2008-10       Impact factor: 2.253

3.  Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.

Authors:  Hiroko Matsumoto; Satoko Ohfuji; Kenji Watanabe; Hirokazu Yamagami; Wakaba Fukushima; Kazuhiro Maeda; Noriko Kamata; Mitsue Sogawa; Masatsugu Shiba; Tetsuya Tanigawa; Kazunari Tominaga; Toshio Watanabe; Yasuhiro Fujiwara; Yoshio Hirota; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2015-02-12       Impact factor: 7.527

Review 4.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

5.  Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies.

Authors:  Ayumi Mugitani; Kazuya Ito; Shin Irie; Takashi Eto; Motoki Ishibashi; Satoko Ohfuji; Wakaba Fukushima; Akiko Maeda; Yoshio Hirota
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

6.  Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.

Authors:  Emmanuel B Walter; Nicola P Klein; A Patricia Wodi; Wes Rountree; Christopher A Todd; Amy Wiesner; Jonathan Duffy; Paige L Marquez; Karen R Broder
Journal:  Pediatrics       Date:  2020-02-06       Impact factor: 7.124

7.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

8.  Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.

Authors:  E Young Bae; Ui Yoon Choi; Hyo Jin Kwon; Dae Chul Jeong; Jung Woo Rhim; Sang Hyuk Ma; Kyung Il Lee; Jin Han Kang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

9.  Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses.

Authors:  Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

10.  Trends in compliance with two-dose influenza vaccine recommendations among children aged 6 months through 8 years.

Authors:  Laura J Pabst; Sandra S Chaves; Cindy Weinbaum
Journal:  Vaccine       Date:  2013-05-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.